425 related articles for article (PubMed ID: 20182025)
41. Amyloid PET in mild cognitive impairment and Alzheimer's disease with BF-227: comparison to FDG-PET.
Furukawa K; Okamura N; Tashiro M; Waragai M; Furumoto S; Iwata R; Yanai K; Kudo Y; Arai H
J Neurol; 2010 May; 257(5):721-7. PubMed ID: 19946781
[TBL] [Abstract][Full Text] [Related]
42. Left lateralized cerebral glucose metabolism declines in amyloid-β positive persons with mild cognitive impairment.
Weise CM; Chen K; Chen Y; Kuang X; Savage CR; Reiman EM;
Neuroimage Clin; 2018; 20():286-296. PubMed ID: 30101060
[TBL] [Abstract][Full Text] [Related]
43. Multiscale deep neural network based analysis of FDG-PET images for the early diagnosis of Alzheimer's disease.
Lu D; Popuri K; Ding GW; Balachandar R; Beg MF;
Med Image Anal; 2018 May; 46():26-34. PubMed ID: 29502031
[TBL] [Abstract][Full Text] [Related]
44. Beta amyloid in Alzheimer's disease: increased deposition in brain is reflected in reduced concentration in cerebrospinal fluid.
Grimmer T; Riemenschneider M; Förstl H; Henriksen G; Klunk WE; Mathis CA; Shiga T; Wester HJ; Kurz A; Drzezga A
Biol Psychiatry; 2009 Jun; 65(11):927-34. PubMed ID: 19268916
[TBL] [Abstract][Full Text] [Related]
45. [Application of positron emission tomography in evaluation of Alzheimer's disease rat model].
He TT; Zhang JM; Wang RM; Yao SL; Tian JH
Zhonghua Yi Xue Za Zhi; 2010 Apr; 90(13):924-7. PubMed ID: 20646515
[TBL] [Abstract][Full Text] [Related]
46. Brain metabolic patterns in patients with suspected non-Alzheimer's pathophysiology (SNAP) and Alzheimer's disease (AD): is [
Chiaravalloti A; Barbagallo G; Martorana A; Castellano AE; Ursini F; Schillaci O
Eur J Nucl Med Mol Imaging; 2019 Aug; 46(9):1796-1805. PubMed ID: 31201430
[TBL] [Abstract][Full Text] [Related]
47. Quantitative μPET Imaging of Cerebral Glucose Metabolism and Amyloidosis in the TASTPM Double Transgenic Mouse Model of Alzheimer's Disease.
Waldron AM; Wyffels L; Verhaeghe J; Bottelbergs A; Richardson J; Kelley J; Schmidt M; Stroobants S; Langlois X; Staelens S
Curr Alzheimer Res; 2015; 12(7):694-703. PubMed ID: 26159204
[TBL] [Abstract][Full Text] [Related]
48. FDG-PET changes in brain glucose metabolism from normal cognition to pathologically verified Alzheimer's disease.
Mosconi L; Mistur R; Switalski R; Tsui WH; Glodzik L; Li Y; Pirraglia E; De Santi S; Reisberg B; Wisniewski T; de Leon MJ
Eur J Nucl Med Mol Imaging; 2009 May; 36(5):811-22. PubMed ID: 19142633
[TBL] [Abstract][Full Text] [Related]
49. Spatial Patterns of Hypometabolism and Amyloid Deposition in Variants of Alzheimer's Disease Corresponding to Brain Networks: a Prospective Cohort Study.
Wang Y; Shi Z; Zhang N; Cai L; Li Y; Yang H; Yao S; Xing X; Ji Y; Gao S
Mol Imaging Biol; 2019 Feb; 21(1):140-148. PubMed ID: 29869063
[TBL] [Abstract][Full Text] [Related]
50. Realizing the potential of positron emission tomography with 18F-fluorodeoxyglucose to improve the treatment of Alzheimer's disease.
Foster NL; Wang AY; Tasdizen T; Fletcher PT; Hoffman JM; Koeppe RA
Alzheimers Dement; 2008 Jan; 4(1 Suppl 1):S29-36. PubMed ID: 18631997
[TBL] [Abstract][Full Text] [Related]
51. Florbetaben to trace amyloid-β in the Alzheimer brain by means of PET.
Barthel H; Sabri O
J Alzheimers Dis; 2011; 26 Suppl 3():117-21. PubMed ID: 21971456
[TBL] [Abstract][Full Text] [Related]
52. Limitations of small animal PET imaging with [18F]FDDNP and FDG for quantitative studies in a transgenic mouse model of Alzheimer's disease.
Kuntner C; Kesner AL; Bauer M; Kremslehner R; Wanek T; Mandler M; Karch R; Stanek J; Wolf T; Müller M; Langer O
Mol Imaging Biol; 2009; 11(4):236-40. PubMed ID: 19214638
[TBL] [Abstract][Full Text] [Related]
53. MiRNA-15b and miRNA-125b are associated with regional Aβ-PET and FDG-PET uptake in cognitively normal individuals with subjective memory complaints.
Vergallo A; Lista S; Zhao Y; Lemercier P; Teipel SJ; Potier MC; Habert MO; Dubois B; Lukiw WJ; Hampel H; ;
Transl Psychiatry; 2021 Jan; 11(1):78. PubMed ID: 33504764
[TBL] [Abstract][Full Text] [Related]
54. Hypometabolism and altered cerebrospinal fluid markers in normal apolipoprotein E E4 carriers with subjective memory complaints.
Mosconi L; De Santi S; Brys M; Tsui WH; Pirraglia E; Glodzik-Sobanska L; Rich KE; Switalski R; Mehta PD; Pratico D; Zinkowski R; Blennow K; de Leon MJ
Biol Psychiatry; 2008 Mar; 63(6):609-18. PubMed ID: 17720148
[TBL] [Abstract][Full Text] [Related]
55. Clinical Relevance of [
Librizzi D; Cabanel N; Zavorotnyy M; Riehl E; Kircher T; Luster M; Hooshyar Yousefi B
Molecules; 2021 Feb; 26(5):. PubMed ID: 33652938
[TBL] [Abstract][Full Text] [Related]
56. Positron emission tomography diagnosis of Alzheimer's disease.
Coleman RE
Neuroimaging Clin N Am; 2005 Nov; 15(4):837-46, x. PubMed ID: 16443494
[TBL] [Abstract][Full Text] [Related]
57. [Amyloid-plaque imaging of the brain using PET].
Ossenkoppele R; Tolboom N; Pijnenburg YA; Lammertsma AA; Scheltens P; van Berckel BN
Ned Tijdschr Geneeskd; 2011; 155():A2981. PubMed ID: 21586182
[TBL] [Abstract][Full Text] [Related]
58. Longitudinal changes of tau PET imaging in relation to hypometabolism in prodromal and Alzheimer's disease dementia.
Chiotis K; Saint-Aubert L; Rodriguez-Vieitez E; Leuzy A; Almkvist O; Savitcheva I; Jonasson M; Lubberink M; Wall A; Antoni G; Nordberg A
Mol Psychiatry; 2018 Jul; 23(7):1666-1673. PubMed ID: 28507319
[TBL] [Abstract][Full Text] [Related]
59. Amyloid imaging.
Villemagne VL; Rowe CC
Int Psychogeriatr; 2011 Sep; 23 Suppl 2():S41-9. PubMed ID: 21729418
[TBL] [Abstract][Full Text] [Related]
60. FDG-PET Patterns Predict Amyloid Deposition and Clinical Profile in Corticobasal Syndrome.
Parmera JB; Coutinho AM; Aranha MR; Studart-Neto A; de Godoi Carneiro C; de Almeida IJ; Fontoura Solla DJ; Ono CR; Barbosa ER; Nitrini R; Buchpiguel CA; Brucki SMD
Mov Disord; 2021 Mar; 36(3):651-661. PubMed ID: 33206389
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
